

## Himalaya targets 12 percent growth in FY15

22 September 2014 | News | By BioSpectrum Bureau

### Himalaya targets 12 percent growth in FY15



In the current fiscal year, Himalaya Drug Company is targeting 12 percent revenue growth, about Rs 1450 crore on robust sales in the domestic market. In the FY14, the company generated Rs 1,300 crore.

"We are looking at clocking Rs 1,450 crore in revenue in the current fiscal year. Our revenue growth is primarily driven by growth in the domestic market," said the company's CEO Mr Philippe Haydon in a statement. He added, "We are constantly exploring new routes to penetrate our brand across new categories, existing markets, new markets, and multiple demographics."

Speaking about the company's business plans, he further added, "Our research pipeline is robust. We are in the advanced stage of drug development for cancer. We are also strengthening our presence in the nutraceuticals segment."

Pharmaceutical and personal care contribute majority of the company's revenue, about 38 percent each. The remaining is contributed by baby care and animal health business.